A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis.

Participants #1, 2, and 3 showed a decreasing trend of 4-HNE during the first 16-week of treatment before levels appeared to rise again ( Figure 3A ; Table 3 ).

also in 47,180 other papers

There were also no differences in the amount of CD25 and FOXP3 protein expression on Tregs, although there was an increasing trend ( Figures 1F , G , respectively).

also in 63,971 other papers